๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers Clinical trials Harbin
Clinical trial register · China

Clinical Trials in Harbin, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Harbin 24 Daqing 5 Mudanjiang 4 Qiqihar 3 Jiamusi 2
Narrow the registerReset
Recruitment status
Phase
Site location
Harbin24 Daqing5 Mudanjiang4 Qiqihar3 Jiamusi2
All 30 locations
Target enrolment
to

Trials with a site in Harbin

24 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Retlirafusp Alfa Combined With Chemotherapy or Fuzuloparib for Triple-Negative Breast Cancer
NCT07752550Triple-Negative Breast Cancer (TNBC)
Harbin Medical University
Phase 2
120
Harbin
2026-07-30
Recruiting
Non-stenting Treatment Strategy for Acute Myocardial Infarction With Non-severe Stenosis(EROSION IV)
NCT07567625Acute Myocardial Infarction (AMI), ST-Segment Elevation Myocardial Infarction(STEMI), Non-ST-Segment Elevation Myocardial Infarction(NSTEMI)
Harbin Medical University
Not applicable
2,000
Harbin, Beijing, Cangzhou, Chengde, Chengdu, Dalian, Daqing, Hunan
2026-07-13
Recruiting
Oral Paclitaxel Plus Fruquintinib Verus Investigator's Choice in Second-Line Advanced Gastric Cancer
NCT07552402Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
Harbin Medical University
Not applicable
150
Shijiazhuang, Harbin, Qiqihar, Baotou, Dalian, Hangzhou
2026-06-10
Active, closed
Low-Dose Radiotherapy With Retlirafusp Alfa and Chemotherapy as Neoadjuvant Therapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
NCT07682376Esophageal Squamous Cell Carcinoma (ESCC)
Harbin Medical University
Phase 2
96
Harbin
2026-06-10
Active, closed
A Real-world Study of Immunotherapy Combination Regimens for Treating Liver Cancer in Cold Regions
NCT07645209Liver Cancer
Harbin Medical University
Observational
1,000
Harbin
2026-05-13
By invitation
A Coronary Computed Tomography Angiography-guided Intervention for High Risk Cardiovascular Disease Population in Rural China
NCT07416344Coronary Artery Disease
Harbin Medical University
Not applicable
14,980
Daqing, Harbin, Hegang, Jiamusi, Mudanjiang, Qiqihar, Shuangyashan, Suihua
2026-04-27
Active, closed
Camrelizumab Plus Risedronate and Chemotherapy for Triple-Negative Breast Cancer: An Exploratory Clinical Study on Mechanisms and Efficacy
NCT07471815Breast Cancer Triple Negative Breast Cancer
Harbin Medical University
Phase 2
30
Harbin
2026-03-04
Active, closed
Time-Restricted Eating for Weight-Loss Maintenance
NCT07163455Overweight or Obese Adults
Harbin Medical University
Not applicable
500
Beijing, Chongqing, Shenzhen, Harbin, Xi'an, Qingdao, Weifang, Chengdu
2026-01-26
Not yet open
Cardiovascular Risk Early Screening and Warning in Harbin : A Prospective Cohort Study
NCT07033624Cardiovascular Diseases
Harbin Medical University
Observational
10,000
Harbin
2025-07-01
Active, closed
Ischemic Stroke Nutrition Intervention Study
NCT06817512Ischemic Stroke
Harbin Medical University
Not applicable
190
Harbin, Mudanjiang, Qiqihar
2025-03-23
Recruiting
Application of Remimazolam Combined With Esketamine in Painless Gastroscopy and Colonoscopy in Elderly Patients
NCT07002801Gastrointestinal Disease
Harbin Medical University
Not applicable
280
Harbin
2025-03-14
Active, closed
Adebrelimab Combined With Dalpiciclib and Standard Endocrine Therapy for HR + / HER2- Breast Cancer
NCT06599216Breast Cancer, HR+/HER2- Breast Cancer
Harbin Medical University
Phase 2
30
Harbin
2024-10-08
Not yet open
Adebrelimab Combined with Irinotecan Liposomes, 5-FU, CF ยฑ Lenvatinib As First-line Treatment for Advanced ICC
NCT06648525Intrahepatic Cholangiocarcinoma (Icc)
Harbin Medical University
Phase 2
68
Harbin
2024-10
By invitation
Constructing a Risk Prediction Model for Intraoperative Hypothermia in Children Under General Anesthesia
NCT06892795Hypothermia, Accidental, Hypothermia; Anesthesia
Harbin Medical University
Observational
562
Harbin
2024-07-15
Recruiting
Single-cell Multi-omics Analyses of OCT-diagnosed Plaque Subtypes in Coronary Artery Disease (MOOP-CAD)
NCT06489119Coronary Artery Disease
Harbin Medical University
Observational
350
Harbin, Changchun
2024-07-07
Recruiting
Preventive Drug-coated Balloon Angioplasty in Vulnerable Atherosclerotic Plaque (RESTORE Trial)
NCT06365502Acute Coronary Syndrome (ACS)
Harbin Medical University
Not applicable
1,860
Beijin, Zunyi, Daqing, Harbin, Jiamusi, Mudanjiang, Zhengzhou, Wuhan
2024-04-16
Recruiting
AK104 in Combination With AK112 Plus Chemotherapy(SOX/XELOX) as First-line Treatment for Advanced G/GEJ Cancer
NCT06196697Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Harbin Medical University
Phase 2
50
Harbin
2024-04-10
Not yet open
A Study of Cadonilimab Combined With AK112 as Second-line Therapy in Patients With Advanced Hepatocellular Carcinoma
NCT06196775Hepatocellular Carcinoma
Harbin Medical University
Phase 2
36
Harbin
2024-01-31
Recruiting
Study on the Improvement of Myocardial Microcirculation After Acute Anterior Myocardial Infarction
NCT06154395Intravascular Imaging and Microvascular Obstruction
Harbin Medical University
Not applicable
90
Harbin
2023-12-20
Recruiting
An Imaging Study of Polyvascular Disease
NCT06016608Polyvascular Disease
Harbin Medical University
Observational
1,100
Harbin
2023-10-18
Active, closed
The Effect of a Psychosomatic Symptom Intervention Program on the Primary Treatment of Differentiated Thyroid Cancer
NCT06422702Pathologically Confirmed Differentiated Thyroid Carcinoma, All Patients Are in the Initial Treatment Phase, Normal Cognitive and Communicative Abilities, Capable of Reading and Understanding Questionnaires in Chinese, Ability to Use a Smartphone
Harbin Medical University
Not applicable
84
Harbin
2023-08-01
Recruiting
Cardioprotective Effect of Dexmedetomidine in Patients With ST-segment Elevation Myocardial Infarction
NCT04912518ST-segment Elevation Myocardial Infarction (STEMI), Percutaneous Coronary Intervention, Cardioprotection
Harbin Medical University
Not applicable
250
Hefei, Lanzhou, Harbin, Mudanjiang, Zhengzhou, Wuhan, Xi'an, Taiyuan
2021-05-27
Rows per page Showing 1–24 of 24
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/harbin

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 24 of those studies with a site in Harbin that also match the filters currently applied.

How many clinical trials are recruiting in Harbin?

9 of the 24 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 4 have not yet opened recruitment, 9 are active but closed to new participants, and 2 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Harbin), 24 studies
PhaseStudiesRecruitingShare
Not applicable10641.7%
Phase 29137.5%
Observational5220.8%

Most active sponsors

Lead sponsors with the most studies (Harbin)
Lead sponsorStudiesRecruiting
Harbin Medical University249
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.